With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22795-99-9,(S)-(1-Ethylpyrrolidin-2-yl)methanamine,as a common compound, the synthetic route is as follows.
To a mixture of cyanuric chloride (0.368 g, 2 mmol) inCH3CN at approximately-10to-20 C was added3-fluoro-p-anisidine (0.28 g, 2 mmol) inCH3CN followed by the additionof N, N diisopropylethylamine (DIEA) (0.35 mL, 2 mmol) and stirred for an hour. The reaction mixture was then allowed to reach room temperature for an hour. The second step was continued without further purification. Cycloheptylamine (0.25 mL, 2 mmol) and DIEA (0.35 mL, 2 mmol) were added and the reaction mixture was stirred overnight at rt. The third step was also preceded without any further purification. S-(-)-2-aminomethyl-N-ethyl pyrrolidine (0.29 mL, 2 mmol) and DIEA (0.35 mL, 2 mmol) were added and the reaction mixture was refluxed overnight. The reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was separated and dried over potassium carbonate, filtered, and concentrated under reduced pressure affording 0.920 g crude material. The crude material was purified by column chromatography to yield a white solid 139 (0.550 g,60%), mp75-77 C ; HPLC: Inertsil ODS-3V C18,40 : 30: 30[KH2P04(O. 01M, pH 3.2) :CH30H :CH3CN], 264 nm, Rt 7.9 min, 95.9% purity; MS (ESI):rnlz 458(M+H, 100).
As the paragraph descriping shows that 22795-99-9 is playing an increasingly important role.
Reference£º
Patent; REDDY US THERAPEUTICS, INC.; WO2004/26844; (2004); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare